EMBC
HEALTHCAREEmbecta Corp
AI Insight
What's Moving EMBC Today?
No stock-specific AI insight has been generated for EMBC yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.76$15.08
$3.13
Fundamentals
Market Cap$188M
P/E Ratio1.7
EPS$1.89
Dividend Yield19.30%
Dividend / Share$0.60
ROE—
Profit Margin10.7%
Debt / Equity—
Trading
Volume2.2M
Avg Volume (10D)—
Shares Outstanding59.3M
EMBC News
26 articles- Securities Fraud Investigation Into Embecta Corp. (EMBC) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. CruzThe AI Journal·Jun 18, 2026
- Embecta Corp. (EMBC) Investigation: Bronstein, Gewirtz & GrossmanThe National Law Review·Jun 17, 2026
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies InvestorsGlobeNewswire·Jun 17, 2026
- embecta appoints Nimish Muzumdar as SVP and President, North AmericaYahoo Finance·Jun 16, 2026
- Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600Yahoo Finance·Jun 5, 2026
- embecta to Participate in Investor EventsYahoo Finance Singapore·Jun 1, 2026
- Embecta (EMBC) Hit With A Sharp Target Cut As Medtech Sentiment WeakensYahoo Finance·May 24, 2026
- Embecta acquires Owen Mumford for $172.6mMedicaldevice-network·May 18, 2026
- Embecta closes Owen Mumford acquisition for up to $201MMedtechdive·May 18, 2026
- Embecta Corp stock (US29082K1051): diabetes specialist updates investors after recent earningsAD HOC NEWS·May 18, 2026
- Embecta Faces U.S. Reset as CEO Bets on GLP-1, Owen Mumford DiversificationMarketbeat·May 16, 2026
- embecta Completes Acquisition of Owen Mumford Holdings LimitedYahoo Finance·May 15, 2026
- S&P Global Ratings Cuts Credit Rating on Embecta (EMBC) After Revenue DeclineYahoo Finance·May 14, 2026
- Why Embecta's (NASDAQ:EMBC) Earnings Are Better Than They SeemYahoo Finance·May 13, 2026
- Embecta Corp. Reported A Surprise Loss, And Analysts Have Updated Their ForecastsYahoo Finance·May 8, 2026
- embecta to Participate at the 2026 BofA Securities Global Health Care ConferenceYahoo Finance·May 8, 2026
- Embecta Corp. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:EMBC) 2026-05-07Seeking Alpha·May 7, 2026
- Embecta (EMBC): Do Buybacks Amid Losses Reveal Capital Discipline or Strategic Uncertainty?Yahoo Finance·May 6, 2026
- Why Embecta Stock Plummeted TodayThe Motley Fool·May 6, 2026
- Embecta Corp. Q2 2026 Earnings Call SummaryMoby·May 5, 2026
- Embecta (EMBC) Q2 2026 Earnings TranscriptMotley Fool·May 5, 2026
- Embecta Q2 Earnings Call HighlightsMarketbeat·May 5, 2026
- embecta Announces Quarterly Cash DividendYahoo Finance·May 5, 2026
- Embecta Corp. Reports Second Quarter Fiscal 2026 Financial ResultsYahoo Finance·May 5, 2026
- How The Embecta (EMBC) Story Is Shifting As Targets Trim While Fair Value HoldsYahoo Finance·Apr 30, 2026
- embecta to Report Fiscal Second Quarter Financial ResultsGlobeNewswire Inc.·Apr 21, 2026
All 26 articles loaded
Price Data
Open$3.04
Previous Close$3.03
Day High$3.17
Day Low$3.01
52 Week High$15.08
52 Week Low$2.76
52-Week Range
$2.76$15.08
$3.13
Fundamentals
Market Cap$188M
P/E Ratio1.7
EPS$1.89
Dividend Yield19.30%
Dividend / Share$0.60
ROE—
Profit Margin10.7%
Debt / Equity—
Trading
Volume2.2M
Avg Volume (10D)—
Shares Outstanding59.3M
About Embecta Corp
Embecta Corp (EMBC) is a prominent medical technology company dedicated to innovating insulin delivery systems for diabetes management. Established as a spin-off from Becton, Dickinson and Company, Embecta offers a wide range of advanced products, including state-of-the-art insulin pens and syringes, designed to improve patient outcomes. With a strong commitment to operational excellence and customer satisfaction, Embecta is strategically poised to leverage growth opportunities in the expanding diabetes care market, thereby reinforcing its leadership role in this critical sector.
HEALTHCAREMEDICAL INSTRUMENTS & SUPPLIES
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICMEDICAL INSTRUMENTS & SUPPLIES
CIK—
Composite FIGI—
Share Class FIGI—